UK markets close in 4 hours 11 minutes

Athenex, Inc. (ATNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.9442-0.0658 (-6.51%)
At close: 04:00PM EST
0.9800 +0.04 (+3.79%)
After hours: 07:58PM EST

Athenex, Inc.

Conventus Building
Suite 600 1001 Main Street
Buffalo, NY 14203
United States
716 427 2950

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees593

Key executives

NameTitlePayExercisedYear born
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.Chairman & CEO480.75k165.82k1960
Mr. Jeffrey M. YordonCOO & Pres of Athenex Pharmaceutical Division693.45k1.64k1949
Dr. Rudolf Kwan M.D., M.B., B.S.Chief Medical Officer483.2kN/A1953
Dr. Allen BarnettCo-Founder & Pres EmeritusN/AN/AN/A
Mr. Steven J. AdamsInterim Chief Accounting OfficerN/AN/A1968
Mr. Michael Smolinski Ph.D.Chief Scientific OfficerN/AN/AN/A
Caileigh DoughertyDirector of Investor RelationsN/AN/AN/A
Ms. Jacqueline LiVP of Alliance Management & Corp. Devel.N/AN/AN/A
Mr. John W. MattheiVP of HRN/AN/AN/A
Dr. Wing-Kai ChanDeputy Chief Medical Officer of Orascovery & Src Kinase PlatformsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Corporate governance

Athenex, Inc.’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.